Animal Parasiticides Market, By Product Type (Ectoparasiticides, Endoparasiticides, and Endectocides), By Animal Type (Companion (Dogs, Cats, Others), Livestock (Bovine, Porcine, Ovine, Poultry, Others)), By Distribution Channel (Veterinary Hospitals & Clinics, Pharmacies, E-commerce, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Dec 2023

Code : CMI9

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Recent Developments

New product launches/approvals

In April 2022, Vetoquinol, a worldwide animal health firm, announced that Felpreva is available for prescription by veterinarians in five European countries: France, Germany, the U.K,, Austria, and Italy. Felpreva is a breakthrough in parasitology for companion animals. It is the first three-month spot-on parasiticide for cats that treats ectoparasites, including hookworms, roundworms, and lungworms, in addition to tapeworms, all in one dosage.
In August 2023, Boehringer Ingelheim, a human and animal health firm, launched the NexGard (afoxolaner) S and M in India. NexGard is a monthly treatment that kills fleas before they can lay eggs, ticks, and mites. It is recommended for use in dogs and puppies starting at eight weeks of age. The chewables have a delicious flavour.
In May 2023, Merck Animal Health, a division of Merck & Co., Inc., announced that BRAVECTO (fluralaner), a novel injectable formulation, has been approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment and prevention of flea infestations for a period of 12 months, as well as for the control of (Rhipicephalus sanguineus) for a period of 11 months, and flea allergy dermatitis (FAD).

Business and Product Acquisitions

In September 2022, Zoetis Inc., a global animal health company, announced the completion of its purchase of Jurox, a privately held animal health company that develops, produces, and markets a diverse range of veterinary medications for livestock and companion animals.
In September 2020, Boehringer Ingelheim, a global pharmaceutical company, and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME have announced a new collaboration that aims to provide novel, microbial-based natural products for the development of next-generation animal health products that combat parasitic diseases.
In July 2020, Merck Animal Health, a division of Merck & Co., Inc., announced the completion of its previously announced acquisition of the U.S. rights to SENTINEL FLAVOR TABS and SENTINEL SPECTRUM Chews in the companion animal category from Virbac.